Geoffrey L. Uy

Hematology

4500 Forest Park Ave
Saint Louis, MO 63108

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 156 publications

Consolidation Therapy Based on Mutation Clearance in Acute Myeloid Leukemia.

Consolidation Therapy Based on Mutation Clearance in Acute Myeloid Leukemia.

Journal: NEJM evidence

Published: August 25, 2026

Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients With Higher-Risk Myelodysplastic Syndromes/Neoplasms: An analysis From the International Consortium for MDS (icMDS).

Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients With Higher-Risk Myelodysplastic Syndromes/Neoplasms: An analysis From the International Consortium for MDS (icMDS).

Journal: American journal of hematology

Published: June 25, 2026

NCCN Guidelines® Insights: Acute Myeloid Leukemia, Version 3.2026.

NCCN Guidelines® Insights: Acute Myeloid Leukemia, Version 3.2026.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: June 15, 2026

Correction: CPX-351 vs. conventional chemotherapy cardiotoxicity in high-risk AML: a post hoc phase III trial analysis.

Correction: CPX-351 vs. conventional chemotherapy cardiotoxicity in high-risk AML: a post hoc phase III trial analysis.

Journal: Cardio-oncology (London, England)

Published: May 23, 2026

Prognostic and therapeutic implications of BRAF mutations in acute myeloid leukemia.

Prognostic and therapeutic implications of BRAF mutations in acute myeloid leukemia.

Journal: Leukemia

Published: March 31, 2026

Regional practice differences significantly impact benefit from post-HCT gilteritinib for FLT3-ITD AML.

Regional practice differences significantly impact benefit from post-HCT gilteritinib for FLT3-ITD AML.

Journal: Blood advances

Published: March 25, 2026

Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE database.

Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE database.

Journal: Blood cancer journal

Published: March 13, 2026

Long-term follow-up of a pediatric regimen for AYA with Ph-negative ALL: 10-year survival of CALGB 10403 (alliance).

Long-term follow-up of a pediatric regimen for AYA with Ph-negative ALL: 10-year survival of CALGB 10403 (alliance).

Journal: Blood advances

Published: January 08, 2026

Long-term Follow-up of a Pediatric Regimen for AYA with Ph-negative ALL: 10-year Survival of CALGB 10403 (Alliance).

Long-term Follow-up of a Pediatric Regimen for AYA with Ph-negative ALL: 10-year Survival of CALGB 10403 (Alliance).

Journal: Blood advances

Published: January 08, 2026

CPX-351 selectively benefits patients with AML and myelodysplasia-related mutations in the pivotal randomized trial.

CPX-351 selectively benefits patients with AML and myelodysplasia-related mutations in the pivotal randomized trial.

Journal: Blood advances

Published: December 11, 2025

CPX-351 Selectively Benefits Patients with AML and Myelodysplasia-Related Mutations in the Pivotal Randomized Trial.

CPX-351 Selectively Benefits Patients with AML and Myelodysplasia-Related Mutations in the Pivotal Randomized Trial.

Journal: Blood advances

Published: December 11, 2025

Prognostic and Therapeutic Implications of BRAF Mutations in Acute Myeloid Leukemia.

Prognostic and Therapeutic Implications of BRAF Mutations in Acute Myeloid Leukemia.

Journal: bioRxiv : the preprint server for biology

Published: November 24, 2025

Showing 1-12 of 156

Last Updated: 09/26/2026